To test the feasibility and efficacy of a multifaceted model of shared care for men after completion of treatment for prostate cancer.
Results
A total of 88 men were randomized (shared care n = 45; usual care n = 43). There were no clinically important or statistically significant differences between groups with regard to distress, prostate cancer-specific quality of life or satisfaction with care. At the end of the trial, men in the intervention group were significantly more likely to prefer a shared care model to hospital follow-up than those in the control group (intervention 63% vs control 24%; P<0.001).
There was high compliance with prostate-specific antigen monitoring in both groups. The shared care model was cheaper than usual care (shared care AUS$1411; usual care AUS$1728; difference AUS$323 [plausible range AUS$91-554]).
Introduction
Increases in cancer incidence and improved survival for many common cancers are placing a growing burden on healthcare systems. International policy is recognizing that the strengths of primary care, and its model of continuous, comprehensive and coordinated care, could be critical to providing affordable cancer care [1] . While this will of course place new burdens on primary care, especially in the context of an ageing population, many countries recognize that primary care offers a more holistic and cost-effective approach to chronic disease management. The challenges facing healthcare systems are well illustrated by the growing incidence and prevalence of prostate cancer, the most common non-cutaneous cancer among men worldwide [2] . The incidence of prostate cancer is projected to rise in many developed countries, largely because of the ageing population and the growing use of PSA as a screening test [3] . In the UK by 2030 it is estimated that 61 000 men will be diagnosed with prostate cancer each year and by 2040 there will be 830 000 prostate cancer survivors [4] . The vast majority of men diagnosed with prostate cancer will survive at least 10 years, leading to very large numbers of prostate cancer survivors [5] .
Men who have completed treatment for prostate cancer require long-term follow-up to detect disease progression, to monitor any adverse effects of treatment and to identify and address psychosocial needs. Observational studies have shown that men treated for prostate cancer frequently experience distressing and ongoing side effects, most notably urinary and bowel incontinence, sexual dysfunction and significant psychological issues [6] [7] [8] . These men have significant levels of unmet need, suggesting that current models of follow-up may be sub-optimal [9, 10] .
Previous trials of follow-up for breast and colon cancer survivors have found no statistically significant differences between primary and secondary care in terms of disease outcomes, psychological morbidity and patient satisfaction [11, 12] . Trials of care shared between primary and secondary care in cancer have mostly focused on increasing the primary care team's involvement in managing symptoms during or immediately after treatment for cancer [13] . These trials have shown that shared care models can improve patient and provider experience of the care process, including patient and provider satisfaction, provider confidence and knowledge, and patient perceptions of care. No trials of shared care have tested a structured approach to sharing cancer surveillance, management of treatment-related effects and psychosocial support between hospital and primary care after completion of treatment. Furthermore, no randomized controlled trials to date have reported prostate cancer follow-up in primary care.
The American Cancer Society has published consensus guidelines about comprehensive survivorship care after treatment for prostate cancer, which have been endorsed by the American Society of Clinical Oncology [14, 15] . These guidelines cover health promotion, cancer surveillance, psychosocial care and management of treatment side effects, and were produced in recognition of the growing role of primary care clinicians and their need for guidance in the care of prostate cancer survivors. In the UK, the National Cancer Survivorship Initiative aimed to provide risk-stratified survivorship care and support primary care to manage a large proportion of cancer survivors, including men with prostate cancer [16] . The objective of the ProCare Trial was to test the feasibility and efficacy of a multifaceted model of shared care for men after completion of treatment for prostate cancer. The model was designed to: identify individual patient needs; tailor information and multidisciplinary referrals; support holistic care coordination by a patient's GP (primary care family physician); improve timeliness and content of communication between hospital and primary care; and reduce burden on hospital clinics. The trial was set within the Medical Research Council framework for the development and evaluation of complex interventions [17, 18] . We aimed to test the feasibility and acceptability of the model of shared care, exclude the potential to cause clinically significant harm, and estimate its efficacy and costs to inform decisions about a potential multi-site phase III trial.
Patients and Methods
As the protocol for the ProCare Trial has been published [19] , in the present paper we report the methods in brief (Australian New Zealand Clinical Trial Registry ACTRN12610000938000).
Study Design
We conducted a multisite randomized controlled trial of two models of follow-up care after men had completed treatment for low-to moderate-risk prostate cancer. Men were recruited from two rural and four urban treatment centres in Victoria and Western Australia between November 2011 and July 2013. The two rural centres in Victoria were 150-280 km from the urban centres in Melbourne. The three treatment centres in Western Australia managed patients from across the whole state, with some men travelling >2 000 km. Treatment centre was a stratifier in the randomization to ensure a balance of men from rural and urban areas between trial groups. Ethics approval was granted from the University of Western Australia's Human Research Ethics Committee (RA/4/1/4447) and from all recruitment sites.
Study Population
Eligible men had completed surgery and/or radiotherapy with curative intent for prostate cancer within the previous 8 weeks, were able to read and write English and had a GP who agreed to participate. Exclusion criteria were: prostate cancer with high risk features (cT3; PSA ≥20 or Gleason score ≥8); men on androgen deprivation therapy (ADT) after completion of radiotherapy; metastatic disease or treatment with palliative intent; or severe cognitive or psychiatric disorder. Men receiving neoadjuvant ADT with radiation treatment were eligible.
Study Procedures
After each participant and his GP had provided informed consent, they were randomly allocated 1:1 to either usual care (control arm) or to trial shared care (intervention arm). Randomization was performed using a centralized independent tele-randomization system at the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, stratified by hospital site and treatment type.
Men in the control group received clinical care according to current hospital practice with visits every 3 months to the treating urologist or radiation oncologist team, consistent with international guidelines [20] . These visits included a PSA test, review of any symptoms and clinical examination, where indicated.
The intervention was based on a shared care model where two of the routine hospital visits during the first 12 months of follow-up were replaced by GP visits (at 6 and 9 months). An additional GP visit shortly after the completion of their treatment for prostate cancer was intended to re-engage the patient with his GP. In addition to the altered schedule of follow-up, the following five components were designed to facilitate shared care: (i) structured systematic communication, using a survivorship care plan (SCP; specific versions for the GP and the participant); (ii) GP clinical management guidelines and local resources; (iii) a register and recall system to prompt the participant and his GP about follow-up appointments; (iv) screening for distress using the Distress Thermometer [21] and unmet needs using a prostate cancer-specific problem checklist [22] ; and (v) patient information resources about prostate cancer and treatment side-effects. We include in the Appendix S1 a checklist according to the Template for Intervention Description and Replication (TIDieR) recommendations [23] and examples of the SCPs and Distress Thermometer.
Outcomes
Patient-reported outcome questionnaires comprised four psychometric measures plus a study-specific question to provide a comprehensive assessment of the various psychosocial and quality-of-life components of this complex intervention [18] . Psychological distress was assessed with the 14-item Hospital Anxiety and Depression Scale (HADS) [24] . Unmet needs were assessed with the Cancer Survivors' Unmet Needs measure (CaSUN) [25] , containing 35 items across five domains (information, patient care, psychosocial, physical, sexual). Prostate cancer-specific quality of life was assessed with the Expanded Prostate Cancer Index Composite (EPIC) [26] , with 32 items across four domains (urinary, bowel, sexual and hormonal function). EPIC has greater coverage of key domains and sensitivity to treatment effects than previous prostate-specific quality-of-life measures [26] . Patient satisfaction with care was assessed with the 18-item Short-form Patient Satisfaction Questionnaire (PSQ-18; 18 items covering access, convenience, continuity, perceived communication between healthcare providers and technical competence) [27] . A single study-specific question assessed patients' preference for future follow-up care (PFC) by asking patients to indicate which of four different options for ongoing follow-up they preferred; we piloted this question before using it in the present trial.
Participants completed the three measures of outcome (HADs, CaSUN and EPIC) at four times points: before randomization and then at 3-, 6-and 12-month follow-up. Participants completed the two measures of process (PSQ-18 and PFC) after their 12-month follow-up appointment.
Clinical process measures (adherence to recommended PSA monitoring; referrals to allied health; prescribing prostatespecific medications) and healthcare resource usage data were obtained by auditing GP medical records and from Medicare Australia national health insurance records, including Medical Benefits Schedule (clinical care items) and Pharmaceutical Benefits Schedule (subsidized drug costs). We examined costs from the health system perspective and therefore did not account for differences in patient-incurred costs. Information on medical services obtained via the Medical Benefits Schedule was reviewed blinded to treatment allocation to identify items of relevance to prostate cancer follow-up and the management of common chronic diseases. Pharmaceutical Benefits Schedule data and GP records were likewise reviewed to identify medications for the following issues: urinary infection; depression; anxiety; bladder dysfunction/urinary symptoms; and erectile dysfunction. Only those health resource usage items that met the criteria specified above were included in the economic analysis. Unit costs for resource usage items were obtained from Medical Benefits Schedule, Pharmaceutical Benefits Schedule and the Independent Hospital Pricing Authority. The cost of the systems used to manage appointments was assumed to be similar across arms and was not factored into the economic analysis.
Sample Size and Statistical Analysis
As the ProCare Trial was designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention, the sample size justification does not employ a statistical hypothesis testing framework. The target sample size of 90 men was calculated to ensure that the 95% CIs for the mean difference between the two groups on the patientreported outcome measures (i.e. HADS, EPIC, CaSUN and PSQ-18) would extend no further than AE0.5 of a standard deviation (SD), with 80% probability and allowing for 10% attrition at 12 months (i.e. complete data on n = 80 was required). This level of precision corresponds to what has been proposed as a minimal clinically important difference of health-related quality-of-life measures [28] .
A statistical analysis plan was prepared before analysis. Participants were analysed according to the intervention they were randomized to receive. The principal emphasis of the analysis was estimation of treatment effect size, and interpretation focused on the CIs of those estimates, using a threshold of AE0.5 SD to define clinically significant benefit and harm [28] . A mixed model for repeated measures was applied to the longitudinal patient-reported scale scores. These models included fixed effect terms for: treatment allocation; time point; time point-by-treatment allocation interaction; and baseline assessment. t-Tests were used to compare randomized groups on the PSQ-18 scales, and chisquared tests were used to compare the groups' responses to the PFC.
Results

Study Population
A total of 493 men were screened for eligibility, of whom 321 (65.1%) were excluded, predominantly because of high risk or metastatic disease (Fig. 1) . Of the remaining 172 men who were eligible according to disease criteria, 88 men and their GPs (51.1% accrual rate) consented to participate and were randomized. Two patients in the shared care arm withdrew from the study shortly after randomization; one man withdrew because he was overwhelmed by the SCP, and the other by the amount of questionnaires and associated paperwork from being in a trial. One GP, with a patient in the shared care arm, withdrew from the trial after the 6-month GP visit. Table 1 presents the baseline characteristics of participants, showing that the two groups were reasonably well balanced.
Study Outcomes
Patient-reported measures Table 2 shows the HADS and EPIC scores, Table 3 the PSQ-18 scores and Table 4 the PFC results. There were no *Randomised but did not meet eligibility criteria because of high risk disease features. 
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© 2016 The Authors BJU International © 2016 BJU International statistically significant differences between groups with regard to distress, prostate-specific quality of life, patient satisfaction or unmet needs. Figure 2 shows the point estimates and 95% CIs for the effect size for each measure relative to the threshold of AE0.5 SD reflecting clinically significant benefit and harm. Of the 37 CIs produced, all but four excluded values indicative of clinically significant harm attributable to the shared care model, and 12 suggested the possibility of benefit (Fig. 2 ).
There was a statistically significant difference in preference for model of care (P = 0.007); men in the shared care arm had a stronger preference for shared care (63%), whilst those in the standard care arm distributed their preferences between shared care (24%), follow-up with treating specialist (34%), and follow-up with available specialist (24%; Table 4 ).
Clinical process measures and healthcare resource use
Adherence to PSA testing recommendations in the usual care arm was 98% at month 3, 93% at month 6, 74% at month 9 and 91% at month 12. For the shared care arm, compliance was 98% at months 3, 6 and 12, and 91% at month 9. Two men had biochemical recurrence of their prostate cancer. Both were in the shared care group and were referred to and seen by a hospital specialist within 1 week of the GP detecting recurrence.
Relative to standard care, shared care was associated with an overall reduction of $323 per patient in direct healthcare costs. This reduction was based on a saving of $590 for two hospital outpatient visits (point estimate only; based on $295 for Medical Oncology consultation from National Efficient Price Determination 2013-2014); but offset to some degree by the following costs: an average $18 increase for medications (95% CI À$31 to $67); a $121 increase for medical services (95% CI À$61 to $304); an extra $128 to develop and discuss the SCP (point estimate only; based on award rate +20% for 2 h oncology nurse work). The plausible range for the overall reduction in cost was $91 to $554 per patient. The lower end of this range was obtained by summing the lowest estimates for each component, and the upper end by summing the highest estimates for each component.
Discussion
ProCare is the first randomized controlled trial to test a model of shared care for the follow-up of men after completion of treatment for low-to moderate-risk prostate cancer. The results suggest that this model of care is feasible to implement, acceptable to participating men and their GPs, broadly similar to standard care in terms of levels of participants' psychological distress, quality of life, unmet needs and satisfaction with care and clinical process measures, and likely to be cheaper than standard care.
Sixty-five per cent of eligible men who were approached and 90% of their GPs agreed to participate. At the end of the trial, those men who had experienced shared care were significantly more likely to prefer a model of care which involved their GP. We acknowledge that there may have been some selection bias, whereby patients who did not like their specialist might be more likely to take part in the study (and more likely to prefer shared care), whereas patients who did not like their GP would be more likely to refuse to take part. The former group of patients, however, should theoretically have been randomized equally between groups. We believe our trial shows that shared care is acceptable for a large proportion of men after treatment for prostate cancer because of convenience, greater involvement of their GP and limited perceived value of short hospital consultations [8, 11, 29] .
This was a phase II trial designed to provide estimates of efficacy on a range of measures and recruitment rates to inform decisions about a larger phase III trial. As described in the protocol paper [19] , our original proposed sample size was larger, but this was adjusted based on more accurate estimates of eligible patients and consent rates. The major issue with recruitment was the higher than expected prevalence of men with high-risk prostate cancer, who were ineligible. Also, during the trial accrual period, there was a significant increase in the use of active surveillance for men with low-or moderate-risk disease, which reduced our pool of eligible men [29] . The hospital specialists involved in this 10 (23) 15 (34) pT2a 2 (5) 6 (14) pT2c 11 (26) 4 (9) *One participant missing baseline questionnaire in shared care; stage T2c.
© 2016 The Authors BJU International © 2016 BJU International 385 trial were concerned about including men at higher risk of recurrence in this trial. This was the first trial of shared care in prostate cancer, and it was felt that we needed to demonstrate the safety of this model in men at lower risk of recurrence before including men with high-risk disease. On the basis of our results, we believe that future such models of care would be suitable for men with high-risk disease.
Whilst ProCare was not undertaken as a formal noninferiority trial, the revised sample size of 90 was designed to ensure that estimates for patient-reported measures were obtained with a level of precision that corresponded to the smallest clinically important effect recommended for patientreported measures (i.e. 0.5 SD) [28] . Nevertheless, the target sample size still provided 65% power to detect differences of at least 0.5 SD and 80% power to detect differences of at least 0.6 SD at the two-sided 5% level of significance. No statistically significant differences were detected between groups on any patient-reported measures but, more importantly, clinically important harms were found to be implausible for 33 of the 37 comparisons performed (based on the width of the 95% CIs). The uncertainty for these remaining four measures (i.e. HADS depression score at 6 months; EPIC hormonal scores at 6 and 12 months; EPIC sexual score at 12 months) is unlikely to be of sufficient concern about safety to warrant a subsequent phase III noninferiority trial.
The ProCare shared care intervention was complex and incorporated several components which were carefully designed based on existing evidence from survivorship care and chronic disease models [30, 31] . To improve communication among providers and between providers and patients, we developed a prostate cancer-specific SCP. There were patient-oriented and GP-oriented versions, the latter providing more detailed clinical practice guidelines and referral information about local allied health providers. SCPs are increasingly being promoted as a standard of care internationally but there remain significant challenges to their implementation [32] . A recent national survey in the USA found that oncologists provide an SCP for <5% of their patients even though their provision is associated with greater involvement of primary care physicians in survivorship care [33] . In our trial, the SCP required up to 2 h of research nurse time to produce, principally because the required information was not easily accessible or extractable from hospital records. Our SCP was a static paper-based document so did not support ongoing communication between healthcare providers, for example in relation to results of PSA monitoring tests. There have been very few randomized clinical trials of SCPs in primary care; the largest trial of SCPs for women with breast cancer followed up in primary care also found no differences in a range of patient-reported measures [34] .
Our intervention included patient and GP reminders aimed to promote compliance with the follow-up schedule. This was effective, with very high compliance rates for PSA monitoring and attendance for follow-up visits. Another important component of effective shared care is the ability to access specialist care rapidly when required [35] . Both men in our trial with biochemical recurrence were seen promptly in specialist care. We believe reminder systems and rapid access to specialist care are key aspects of effective shared care for people with cancer but their ease of implementation into routine practice will vary in different healthcare settings.
For the first time in a trial of cancer follow-up, we incorporated the Distress Thermometer and a prostate cancer-specific problem prompt list as part of the primary care package of care delivery [21, 22] . Based on the audit of GP records there was some limited evidence of use of the tool in general practice and subsequent referrals to psychologists, physiotherapists and prescribing specific drugs (detailed results not shown but incorporated in healthcare resource use analysis); however, we did not observe any statistically significant difference in our measure of unmet needs. Previous trials in hospital care of screening for distress and unmet needs have had, at best, small or equivocal results [36, 37] . Although based on limited process measures, our results do not add any weight to support use of this aspect of the intervention.
There are alternative models of care which have been examined to manage the growing number of cancer survivors. These include, for example, hospital nurse-led models [38] and telemedicine approaches [39] . While both of these are potentially effective, either in reducing demand on hospital specialists or minimizing travel burden for patients, they fail to engage primary care. In the UK, models of self-directed care for men at low risk of prostate cancer recurrence are also being deployed to reduce medical visits and associated costs [16] .
In summary, our novel trial of shared care for men with treated prostate cancer has demonstrated this is an acceptable and feasible model of care that appears to deliver similar outcomes to current practice at lower cost. This is consistent with findings from trials of primary care follow-up for breast and colorectal cancer [11, 12] . The core elements of the care model included an SCP, recall and reminders for patients and GPs and rapid access to specialist care when required. Whether a larger phase III trial is required to justify a change in practice requires further consideration. Future trials of shared care for prostate cancer should consider broadening the population to include men with high-risk disease or those on active surveillance.
